Changzhou Pacific Pharmaceutical Research Institute

Changzhou Pacific Pharmaceutical Research Institute is a pharmaceutical research organization based in Changzhou, China, primarily focused on the development of small molecule therapeutics. It operates as the core research and development arm for the broader Changzhou Pacific Pharmaceutical group, specializing in cardiovascular and metabolic diseases. The institute is well-regarded for its work on high-quality generic medications, including the widely prescribed antihypertensive amlodipine besylate. Its capabilities span chemical synthesis, formulation development, and clinical research support. The institute plays a critical role in bringing cost-effective treatments to the Chinese domestic market through rigorous R&D processes. By maintaining a focus on essential medicines, the organization supports the industrial output of its parent company and contributes to regional pharmaceutical innovation.